Pharmacology of irinotecan

Drugs of Today

Volumn 34, Issue 9, 1998, Pages 777-803

  Robert, Jacques ^a   Rivory, Laurent ^b  

^a INSTITUT BERGONIÉ   (France)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; IRINOTECAN; PRODRUG;

ANTINEOPLASTIC ACTIVITY; CHINESE MEDICINE; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PHARMACODYNAMICS; REVIEW;

EID: 0031736659     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.9.485276     Document Type: Review

References (186)

1. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T., Sim, G.A. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966, 88: 3888-90.
2. Gallo, R.C., Whang-Peng, J., Adamson, R.H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 1971, 46: 789-95.
3. Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T., Block, J.B. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970, 54: 461-70.
4. Muggia, F.M., Creaven, P.J., Hansen, H.H., Cohen, M.N., Selawry, D.S. Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies. Cancer Chemother Rep 1972, 56: 515-2.
5. Moertel, C.G., Schutt, A.J., Reitemeier, R.J., Hahn, R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972, 56: 95-101.
6. Wani, M.C., Ronman, P.E., Lindley, J.T., Wall, M.E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 1980, 23: 554-60.
7. Hsiang, Y.H., Hertzberg, R., Hecht, S., Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260: 14873-8.
8. Hsiang, Y.H., Wu, H.Y., Liu, L.F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988, 48: 3230-5.
9. Hsiang, Y.H., Lihou, M.G., Liu, L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989, 49: 5077-82.
10. Mattern, M.R., Hofmann, G.A., McCabe, F.L., Johnson, R.K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991, 51: 5813-6.
11. Jaxel, C., Kohn, K.W., Wani, M.C., Wall, M.E., Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and relation to antitumor activity. Cancer Res 1989, 49: 1465-9.
12. D'Arpa, P., Liu, L.F. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989, 989: 163-77.
13. Liu, L.F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989, 58: 351-75.
14. Sawada, S., Okajima, S., Aiyama, R. et al. Synthesis and antitumor activity of 20(S)camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10- hydroxy-camptothecin. Chem Pharm Bull 1991, 39: 1446-54.
15. Kingsbury, W.D., Boehm, J.C., Jakas, D.R. et al. Synthesis of water-soluble (aminoalkyl)-camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Am Chem Soc 1991, 34: 98-107.
16. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11. in the antitumor effect of CPT-11. Cancer Res 1991, 51: 4187-91.
17. Kaneda, N., Nagata, H., Furuta, T., Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990, 50: 1715-20.
18. Fassberg, J., Stella, V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992, 81: 676-84.
19. Akimoto, K., Kawai, A., Ohya, K. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull 1994, 42: 2135-8.
20. Crow, R.T., Crowthers, D.M. Structural modifications of camptothecin and effects on topoisomerase I inhibition. J Med Chem 1992, 35: 4160-4.
21. Burke, T.G., Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 1993, 212: 285-7.
22. Burke, T.G., Mi, Z. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J Med Chem 1994, 37: 40-6.
23. Burke, T.G., Munshi, C.B., Mi, Z., Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995, 84: 518-9.
24. Wang, J.C. DNA topoisomerases. Annu Rev Biochem 1996, 65: 635-92.
25. Andersen, A.H., Svejstrup, J.Q., Westergaard, O. The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II. Adv Pharmacol 1995, 29A: 83-102.
26. Gupta, M., Fujimori, A., Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995, 1262: 1-14.
27. Stewart, L., Redinbo, M.R., Qui, X.Y., Hol, W.G.J., Champoux, J.J. A model for the mechanism of human topoisomerase I. Science 1998, 279: 1504-13.
28. Been, M.D., Burgess, R.R., Champoux, J.J. Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV4O DNA. Nucl Acid Res 1984, 12: 3097-111.
29. Hertzberg, R.P., Caranfa, M.J., Hecht, S. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28: 4629-38.
30. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K.W., Pommier, Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 1991, 266: 20418-23.
31. Tanizawa, A., Kohn, K.W., Pommier, Y. Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucl Acid Res 1993, 21: 5157-66.
32. Tanizawa, A., Fujimori, A., Fujimori, Y., Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994, 86: 836-42.
33. Tanizawa, A., Kohn, K.W., Kohlhagen, G., Leteurtre, F., Pommier, Y. Differential stabilization of eukaryotic DNA topoisomerase I deavable complexes by camptothecin derivatives. Biochemistry 1995, 34: 7200-6.
34. Zhang, H., D'Arpa, P., Liu, L.F. A model for tumour cell killing by topoisomerase poisons. Cancer Cells 1990, 2: 23-7.
35. Ryan, A.J., Squires, S., Strutt, H.L., Johnson, R.T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucl Acid Res 1991, 19: 3295-300.
36. Christiansen, K., Dirac Svejstrup, A.B., Andersen, A.M., Westergaard, O. Eukaryotic topoisomerase I-mediated cleavage requires bipartite DNA interaction. Cleavage of DNA substrates containing strand interruptions implicates a role for topoisomerase I in illegitimate recombination. J Biol Chem 1993, 268: 9690-701.
37. Cortes, F., Pinero, J., Ortiz, T. Importance of replication fork progression for the induction of chromosome damage and SCE by inhibitors of DNA topoisomerases. Mutat Res 1993, 303: 71-6.
38. Del Bino, G., Darzynkiewicz, Z. Camptothecin. teniposide, or 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells. Cancer Res 1991, 51: 1165-9.
39. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996, 56: 4430-7.
40. Wang, Y., Perrault, A.R., Iliakis, G. Down-regulation of DNA replication in extracts of camptothecin-treated cells: Activation of an S-phase checkpoint? Cancer Res 1997, 57: 1654-9.
41. Gong, J., Li, X., Darzynkiewicz, Z. Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin. J Cell Physiol 1993, 157: 263-70.
42. Chen, A.Y., Yu, C., Potmetsil, M., Wall, M.E., Wani, M.C., Liu, L.F. Camptothecin over-comes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991, 51: 6039-44.
43. Hendricks, C.B., Rowinsky, E.K., Grochow, L.B., Donehower, R.C., Kaufmann, S.H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992, 52: 2268-78.
44. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., Matsumoto, K. Antitumour activity of a camptothecin derivative, CPT-11, against human tumour xenografts in nude mice. Cancer Chemother Pharmacol 1991, 28: 192-8.
45. Kanzawa, F., Sugimoto, Y., Minato, K. et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res 1990, 50: 5919-24.
46. Niimi, S., Nakagawa, K., Sugimoto Y. et al. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 1992, 52: 328-33.
47. Woessner R.D., Eng, W.K., Hofmann, G.A. et al. Camptothecin hyper-resistant P388 cells: Drug-dependent reduction in topoisomerase I content. Oncol Res 1992, 4: 481-8.
48. Madden, K.R., Champoux, J.J. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res 1992, 52: 525-32.
49. Takeda, S., Shimazoe, T., Sato, K., Sugimoto, Y., Tsuruo, T., Kono, A. Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: Detected by RNA/PCR-based quantitation assay. Biochem Biophys Res Commun 1992, 184: 618-25.
50. Beidler, D.R., Cheng, Y.C. Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 1995, 47: 907-14.
51. Matsumoto, Y., Fujiwara, T., Honjo, Y., Sasaoka, N., Tsuchida, R., Nagao, S. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol 1993, 53: 97-103.
52. Niwa, K., Misao, R., Hanabayashi, T. et al. Semi-quantitative analysis of DNA-topoisomerase I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: Its relation to cytotoxicity against camptothecin derivative. Jpn J Cancer Res 1994, 85: 869-74.
53. McLeod, H.L., Keith, W.N. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996, 74: 508-12.
54. Chang, J.Y., Dethlefsen, L.A., Barley, L.R., Zhou, B.S., Cheng, Y.C. Characterisation of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 1992, 43: 2443-52.
55. Madelaine, I., Prost, S., Naudin, A., Riou, G., Lavelle, F., Riou, J.F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol 1993, 45: 339-48.
56. Kijima, T., Kubota, N., Nishio, K. Establishment of a CRT-11-resistant human ovarian cancer cell line. Anticancer Res 1994, 14: 799-804.
57. Kapoor, R., Slade, D.L., Fujimori, A., Pommier, Y., Harker, W.G. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 1995, 7: 83-95.
58. Eng, W.K., McCabe, F.L., Tan, K.B. et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990, 38: 471-80.
59. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T., Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990, 50: 6925-30.
60. Tanizawa, A., Pommier, Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 1992, 52: 1848-54.
61. Kubota, N., Kanzawa, F., Mishio, K. et al. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 1992, 188: 571-7.
62. Wang, L.F., Ting, C.Y., Lo, C.K. et al. Identifications of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res 1997, 57: 1516-22.
63. Fujimori, A., Harker, W.G., Kohlhagen, G., Hoki, Y., Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 1995, 55: 1339-46.
64. Tamura, H., Kohchi, C., Yamada, R. et al. Molecular cloning of a cDNA camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucl Acid Res 1991, 19: 69-75.
65. Gromova, I.I., Kjeldsen, E., Svejstrup, J.Q., Alsner, J., Christiansen, K., Westergaard, O. Characterization of an altered DNA catalysis of a camptotecin-resistant eukaryotic topoisomerase I. Nucl Acid Res 1993, 21: 593-600.
66. Tanizawa, A., Bertrand, R., Kohlhagen, G., Tabuchi, A., Jenkins, J., Pommier, Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem 1993, 268: 25463-8.
67. Li, X.G., Haluska, P., Hsiang, Y.H. et al. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem Pharmacol 1997, 53: 1019-27.
68. Beidler, D.R., Chang, J.Y., Zhou, B.S., Cheng, Y.C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 1996, 56: 345-53.
69. Fujimori, A., Gupta, M., Hoki, Y., Pommier, Y. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol 1996, 50: 1472-8.
70. Goldwasser, F., Bae, I., Valenti, M., Torres, K., Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995, 55: 2116-21.
71. Andoh, T., Ishii, K., Susuki, Y. et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 1987, 84: 5565-9.
72. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L.F., Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cells lines. Cancer Res 1990, 50: 7962-5.
73. Cortes, F., Pinero, J. Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemother Pharmacol 1994, 34: 411-5.
74. Bertrand, R., O'Connor, P.M., Kerrigan, D., Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992, 28A: 743-8.
75. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumour xenografts in nude mice. Int J Cancer 1992, 50: 760-6.
76. Boothman, D.A., Wang, M., Schea, R.A., Burrows, H.L., Strickfaden, S., Owens, J.K. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys 1992, 24: 939-48.
77. Li, C.J., Averboukh, L., Pardee, A.B. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem 1993, 268: 22463-8.
78. Mattern, M.R., Hofmann, G.A., McCabe, F.L., Johnson. R.K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991, 51: 5813-6.
79. Roffler, S.R., Chan, J., Yeh, M.Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 1994, 54: 1276-85.
80. Chen, A.Y., Okunieff. P., Pommier, Y., Mitchell, J.B. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 1997, 57: 1529-36.
81. Minagawa, Y., Kigawa, J., Ishihara, H., Itamochi, H., Terakawa, N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 1994, 85: 966-71.
82. Fukuda, M., Nishio, K., Kanzawa, F. et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38. in human small cell lung cancer cells. Cancer Res 1996, 56: 789-93.
83. Kotoh, S., Naito, S., Yokomizo, A. et al. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 1994, 54: 3248-52.
84. Matsuoka, H., Yano, K., Seo, Y. et al. Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact sensitive plates. Anticancer Drugs 1995, 6: 413-8.
85. Bissery, M.C., Vrignaud, P., Lavelle, F., Chabot, G.G. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-cancer Drugs 1996, 7: 437-60.
86. Shimada, Y., Rothenberg, M., Hilsenbeck, S.G., Burris, H.A., Degen, D., Von Hoff, D.D. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994, 5: 202-6.
87. Tsuruo, T., Matsusaki, T., Matsushita, M., Saito, H., Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988, 21: 71-4.
88. Mattern, M.R., Hofman, G.A., Polsky, R.M., Funk, L.R., McCabe, F.L., Johnson, R.K. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug resistant cells. Oncol Res 1993, 5: 467-74.
89. Guichard, S., Cussac, D., Hennebelle, I., Bugat, R., Canal. P. Sequence-dependent activity of the irinotecan-5-fluorouracil combination in the human colon cancer model HT-29 in vitro and in vivo. Int J Cancer, in press.
90. Kunimoto, T., Nitta, K., Tanaka, T. et al. Antitumor activity of 7-ethyl-10-(-4-[1-piperidino]-1-piperidino)-carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987, 47: 5944-7.
91. Houghton, P.J., Cheshire, P.J., Hallman, J.C., Bissery, M.C., Mathieu-Boué, A., Houghton, J.A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(-4-[1-piperidino]-1-piperidino)-carbonyloxycamptothecin against human tumor xenographs: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993, 53: 2823-9.
92. Houghton, P.J., Cheshire, P.J., Hallman, J.C. et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36: 393-403.
93. Vassal, G., Terrier-Lacombe, M.J., Bissery, M.C. et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996, 74: 537-45.
94. Hare, C.B., Elion, G.B., Houghton, P.J. et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(-4-[1-piperidino]-1 -piperidino)carbonyloxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1997, 39: 187-91.
95. Thomson, J., Zamboni, W.C., Cheshire, P.J. et al. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 1997, 8: 313-22.
96. Kudoh, S., Takada, M., Masuda, N. et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993, 84: 203-7.
97. Houghton, J.A., Cheshire, P.J., Hallman, J.D. et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996, 2: 108-18.
98. Kaneda, N., Yokokura, T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 1990, 50: 1721-5.
99. Araki, E., Ishikawa, M., Iigo, M., Koide, M., Itabashi, M., Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993, 84: 697-702.
100. 14C]SN-38 to rats. Biol Pharm Bull 1995, 18: 1114-9.
101. Negoro, S., Fukuoka, M., Masuda, N. et al. Phase 1 study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991, 83: 1164-8.
102. Rothenberg, M.L., Kuhn, J.G., Burris, H.A. et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11: 2194-204.
103. de Forni, M., Bugat, R., Chabot, G.G. et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994, 54: 4347-54.
104. Rowinsky, E.K., Grochow, L.B., Ettinger, D.S. et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994, 54: 427-36.
105. Abigerges, D., Chabot, G.G., Armand, J.P., Hérait, P., Gouyette, A., Gandia, D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13: 210-21.
106. Catimel G., Chabot G.G., Guastalla, J.P. et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every 3 weeks in patients with advanced solid tumors. Ann Oncol 1995, 6: 133-40.
107. Ohe, Y., Sasaki, Y., Shinkai, T. et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992, 84: 972-4.
108. Armand, J.P., Extra, J.M., Catimel, G., Abigerges, D., Marty, M., Clavel, M. Rationale for the dosage and schedules of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996, 7: 837-42.
109. Merrouche, Y., Extra, J.M., Abigerges, D. et al. High-dose intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study. J Clin Oncol 1997, 15: 1080-6.
110. Gandia, D., Abigerges, D., Armand, J.P. et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993, 11: 196-7.
111. Saliba, F., Hagipantelli, R., Misset, J.L. et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment. J Clin Oncol 1998, 16: 2745-51.
112. Masuda, N., Fukuoka, M., Kudoh, S. et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993, 68: 777-82.
113. Shinkai, T., Arioka, H., Kunikane, H. et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidinoJcar-bonyloxycamptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 1994, 54: 2636-42.
114. Masuda, N., Fukuoka, M., Kudoh, S. et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimultating factor support for advanced non-small cell lung cancer. J Clin Oncol 1994, 12: 90-6.
115. Masuda, N., Fukuoka, M., Kudoh, S. et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant granulocyte colony-stimultating factor support for advanced lung cancer. J Clin Oncol 1994, 12: 1833-41.
116. Armand, J.P., Ducreux, M., Mahjoubi, M. et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995, 31A: 1283-7.
117. Shimada, Y., Yoshino, M., Wakui A. et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11: 909-13.
118. Conti, J.A., Kemeny, N.B., Saltz, L.B. et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14: 709-15.
119. Rothenberg. M.L., Eckardt, J.R., Kuhn, J.G. et al. Phase II trial of irinotecan inpatients wth progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996, 14: 1128-35.
120. Rougier, P., Bugat, R., Douillard, J.Y. et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15: 251-60.
121. Fukuoka, M., Nitani, H., Suzuki, A. et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992, 10: 16-20.
122. Verschraegen, C.F., Levy, T., Kudelka, A.P. et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997, 15: 625-31.
123. Ohno, R., Okada, K., Masaoka, T. et al. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990, 8: 1907-12.
124. Tsuda, H., Takatsuki, K., Ohno, R. et al. Treatment of adult T-cell leukemia-lymphoma with irinotecan hydrochloride. Br J Cancer 1994, 70: 771-4.
125. Wagener, D.J., Verdonk, H.E., Dirix, L.Y. et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an Early Clinical Trials Group study. Ann Oncol 1995, 6: 129-32.
126. Bonneterre, J., Pion, J.M., Adenis, A. et al. A phase II study of a new camptothecin analog CPT-11 in previously treated advanced breast cancer patients. Proc Am Soc Clin Oncol 1993, 12: 94.
127. Ducreux, M., Rougier, P., Ychou, M. et al.
128. Shirao, K., Shimada, Y., Kondo, H. et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Cin Oncol 1997, 15: 921-7.
129. Oshita, F., Noda, K., Nishiwaki, Y. et al. Phase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer. J Clin Oncol 1997, 15: 304-9.
130. Satoh, T., Hosokawa, M., Atsumi, R., Susuki, W., Hakusui, H., Nagai, E. Metabolic activation opf CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994, 17: 662-41.
131. Barilero, I., Gandia, D., Armand, J.P. et al. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: Application to plasma pharmacokinetic studies in cancer patients. J Chromatogr 1992, 575B: 275-80.
132. Sumiyoshi, H., Fujiwara, Y., Ohune, T., Yamaoka, N., Tamura, K., Yamakido, M. High-performance liquid Chromatographic determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma. J Chromatogr 1995, 670B: 309-16.
133. Rivory, L.P., Robert, J. Reversed-phase high-performance liquid Chromatographic method for the simultaneous quantisation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr 1994, 661B: 133-41.
134. Warner, D.L., Burke, T.G. Simple and versatile high-performance liquid Chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr 1997, 691B: 161-71.
135. Rivory, L.P., Chatelut, E., Canal, P., Mathieu-Boué, A., Robert, J. Kinetics of the in vivo interconversion of the lactone and carboxylate forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994, 54: 6330-3.
136. Gupta, E., Mick, R., Ramirez, J. et al. Pharmacokinetic and pharmacodynamic irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996, 14: 2688-95.
137. Sasaki, Y., Ohtsu, A., Shimada, Y., Ono, K., Saijo, N. Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994, 86: 1096-8.
138. Sasaki, Y., Hakusui, H., Mizuno, S. et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995, 86: 101-10.
139. Sasaki, Y., Yoshida, Y., Sudoh, K. et al. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPR-11. Jpn J Cancer Res 1995, 86: 111-6.
140. Kudoh, S., Fukuoka, M., Masuda, N. et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 1995, 86: 406-13.
141. Saltz, L.B., Kanowitz, J., Kemeny, N.E. et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996, 14: 2959-67.
142. Rivory, L.P., Haaz, M.C., Canal, P., Lokiec, F., Armand, J.P., Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997, 3: 1261-6.
143. Rivory, L.P., Robert, J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995, 36: 176-9.
144. Gupta, E., Lestingi, T.M., Mick, R., Ramirez, J., Vokes, E.E., Ratain, M.J. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 1994, 54: 3723-5.
145. Rivory, L.P., Riou, J.F., Haaz, M.C. et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996, 56: 3689-94.
146. Bourzat, J.D., Vuilhorgne, M., Rivory, L.P., Robert, J., Commerçon, A. Semi-synthesis of RPR 121056A, a major metabolite of irinotecan (CPT-11). Tetrahedron Lett 1996, 37: 6327-30.
147. Lokiec, F., Canal, P., Gay, C. et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995, 36: 79-82.
148. Chu, X.Y., Kato, Y., Niinuma, K., Sudo, K.I., Hakusui, H., Sugiyama, Y. Muftispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 1997, 281: 304-14.
149. Gupta, E., Safa, A.R., Wang, X., Ratain, M.J. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporine A. Cancer Res 1996, 56: 1309-14.
150. Fagbemi, S., Iyer, L., Mani, S. et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A. Proc Am Soc Clin Oncol 1997, 16: 219a.
151. Chabot, G.G., Abigerges, D., Catimel, G. et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995, 6: 141-51.
152. Chabot, G.G. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 1995, 36: 463-72.
153. Sasaki, Y., Mizuno, S., Fujii, H. et al. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 1995, 86: 117-23.
154. Mick, R., Gupta, E., Vokes, E.E., Ratain, M.J. Limited sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol 1996, 14: 2012-9.
155. Yamamoto, N., Tamura, T., Karato, A. et al. CPT-11: Population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn J Cancer Res 1994, 8: 972-7.
156. Nakashima, H., Lieberman, R., Karato, A. et al. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): Implications for area under the concentration-time curve monitoring. Ther Drug Monit 1995, 17: 221-9.
157. Yamamoto, N., Tamura, T., Nishiwaki, Y. et al. Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial. Clin Cancer Res 1997, 3: 1087-92.
158. Tsuji, T., Kanada, N., Kado, K., Yokokura, T., Yoshimoto, T., Tsuru D. CPT-11-converting enzyme from rat serum: Purification and some properties. J Pharmacobio-Dyn 1991, 14: 341-9.
159. Senter, P.D., Marquardt, H., Thomas, B.A., Hammock, B.D., Franck, I.S., Svensson, H.P. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res 1996, 56: 1471-4.
160. Atsumi, R., Okasaki, O., Kakusui, H. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biol Pharm Bull 1995, 18: 1024-6.
161. Ketterman, A.J., Bowles, M.R., Pond, S.M. Purification and characterization of two human liver carboxylesterases. Int J Biochem 1989, 21: 1303-12.
162. Rivory, L.P., Bowles, M.R., Robert, J., Pond, S.M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996, 52: 1103-11.
163. Haaz, M.C., Rivory, L.P., Riché, C., Robert, J. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmied Arch Pharmacol 1997, 356: 257-62.
164. Atsumi, R., Suzuki, W., Hakusui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991, 21: 1159-69.
165. Haaz, M.C., Rivory, L.P., Jantet, S., Ratanasavanh. D., Robert, J.
166. Iyer, L., King, D.D., Whitington, P.F. et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of UDP-glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998, 101. 847-54.
167. Wasserman, E., Cvitkovic, E., Goldwasser, F. et al. Oxaliplatin/CPT-11 combination: Preliminary results of a phase I study of an active combination in gastrointestinal malignancies. Proc Am Assoc Cancer Res 1997, 38: 224.
168. Wasserman, E., Myara, A., Lokiec F., et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports. Ann Oncol 1997, 8: 1049-51.
169. Takasuna, K., Hagiwara, T., Hirohashi, M. et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996, 56: 3752-7.
170. Narita, M., Nagai, E., Hagiwara, H. et al. Inhibition of β-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 1993, 23: 5-10.
171. Takasuna, K., Kasai, Y., Kitano, Y. et al. Preventive effects of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11) in rats. Jpn J Cancer Res 1995, 86: 978-84.
172. Yokoi, T., Narita, M., Nagai, E. et al. Inhibition of UDP-glucuronosyltransferase by aglycones of natural glucuronides in Kampo medicines using SN-38 as a substrate. Jpn J Cancer Res 1995, 86: 985-9.
173. Haaz, M.C., Rivory, L.P., Riche, C., Vernillet, L., Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P450 3A and drug interactions. Cancer Res 1998, 58: 468-72.
174. Dodds, H.M., Haaz, M.C., Riou, J.F., Robert, J., Rivory, L.P. Identification of a new metabolite of irinotecan (CPT-11). I. Pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 1998, 286: 578-83.
175. Haaz, M.C., Riché, C., Rivory, L.P., Robert, J. Biosynthesis of an aminopiperidino metabolite of irinotecan by human hepatic microsomes. Drug Metab Dispos 1998, 26: 769-74.
176. Lokiec, F., Monégier du Sorbier, B., Sanderink, G.J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 1996, 2: 1943-9.
177. Akimoto, K., Kawai, A., Ohya, K. Simultaneous determination of a camptothecin derivative, used as an anticancer drug, and its photodegradation products by high-performance liquid chromatography. J Chromatogr 1996, 734A: 401-4.
178. Dodds, H.M., Craik, D.J., Rivory, L.P. Photodegradation of irinotecan (CPT-11) in aqueous solutions: Identification of fluorescent products and influence of solution composition. J Pharm Sci 1997, 86: 1410-6.
179. Jansen, W.J.M., Zwart, B., Hulscher, S.T.M., Giaccone, G., Pinedo, H.M., Boven, E. CPT-11 in human colon cancer cell lines and xenografts: Characterization of cellular sensitivity determinants. Int J Cancer 1997, 70: 335-40.
180. Van Ark-Otte, J., Kedde, M.A., van der Vijgh, W.J.F. et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 1998, 77: 2171-6.
181. Ogasawara, H., Nishio, K., Kanzawa, F. et al. Intracellular carboxylesterase activity as a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn J Cancer Res 1995, 86: 124-9.
182. Natelson, E.A., Giovanella, B.C., Verschraegen, C.F. et al. Phase I and pharmacological studies of 20(S)-camptothecin and 20(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 1996, 803: 224-30.
183. Creamers, G., Gerrits, C., Eckardt, J. et al. Phase I and pharmacological study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997, 15: 1087-93.
184. Von Hoff, D.D., Rothenberg, M., Pitot H. et al. Irinotecan therapy for patients with previously treated metastatic colorectal cancer: Overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997, 16: 228a.
185. Perego, P., Capranico, G., Supino, R., Zunino, F. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 1994, 5: 645-9.
186. Subramanian, D., Kraut, E., Staubus, A., Young, D.C., Muller, M.T. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995, 55: 2097-103.